SDF-1 Activators
SDF-1, also known as CXCL12, plays a pivotal role in various cellular processes, including migration, homing, and activation, through its interaction with the CXCR4 receptor. While direct activators of SDF-1 are not listed here due to the specificity criteria, several chemicals have been identified as modulators of SDF-1-induced cellular responses through indirect means. Antagonists such as AMD3100 and SB225002 specifically target CXCR4 and CXCR2, respectively, disrupting the binding of SDF-1 to its receptor and preventing downstream signaling events. Inhibitors of key signaling pathways, such as TGX-221 targeting PI3K, U0126 targeting MEK1/2, and SP600125 targeting JNK, disrupt the intracellular cascades triggered by SDF-1, influencing cellular responses such as migration and activation.
Compounds like NSC23766, a Rac1 inhibitor, and Lestaurtinib, a JAK2 inhibitor, specifically target proteins involved in the SDF-1/CXCR4 signaling pathway, providing means to modulate downstream events. SB203580, a p38 MAPK inhibitor, and Wortmannin, a PI3K inhibitor, disrupt signaling cascades implicated in SDF-1 activation, influencing cellular responses. LY303511, an analog of LY294002, and GSK2334470, a PDK1 inhibitor, target the PI3K/Akt pathway, providing additional tools to study and manipulate cellular responses mediated by the SDF-1/CXCR4 axis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 is a selective inhibitor of PI3K, a key signaling pathway involved in SDF-1-mediated activation. PI3K inhibition with TGX-221 disrupts the downstream signaling events triggered by SDF-1, influencing cellular responses such as migration and activation mediated by the SDF-1/CXCR4 axis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific phosphoinositide 3-kinase (PI3K) inhibitor, targeting the PI3K/Akt signaling pathway. This pathway is implicated in the activation of SDF-1. LY294002 disrupts the signaling cascade, affecting the downstream events mediated by SDF-1 through modulation of the PI3K pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), a kinase involved in stress response pathways implicated in SDF-1 activation. By inhibiting JNK with SP600125, the stress response pathway is disrupted, leading to altered SDF-1-mediated signaling and downstream cellular responses, including migration and activation through CXCR4. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Lestaurtinib is a JAK2 inhibitor that can influence the JAK/STAT signaling pathway implicated in SDF-1 activation. By inhibiting JAK2, Lestaurtinib disrupts the downstream signaling cascades triggered by SDF-1, modulating cellular responses such as migration and activation through the SDF-1/CXCR4 axis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor, and the p38 MAPK pathway is involved in the activation of SDF-1. By inhibiting p38 MAPK with SB203580, the downstream signaling events triggered by SDF-1 are disrupted, influencing cellular responses such as migration and activation mediated by the SDF-1/CXCR4 axis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor, and the PI3K/Akt signaling pathway is implicated in the activation of SDF-1. Wortmannin disrupts the signaling cascade, affecting downstream events triggered by SDF-1 and modulating cellular responses such as migration and activation through the SDF-1/CXCR4 axis. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is an analog of LY294002 and acts as a selective inhibitor of phosphoinositide 3-kinase (PI3K), influencing the PI3K/Akt signaling pathway. This pathway is implicated in the activation of SDF-1, and LY303511 disrupts the signaling cascade, affecting the downstream events triggered by SDF-1 and modulating cellular responses such as migration and activation through the SDF-1/CXCR4 axis. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $199.00 $1165.00 | 1 | |
GSK2334470 is a specific inhibitor of PDK1 (3-phosphoinositide-dependent protein kinase-1), a kinase involved in the PI3K/Akt signaling pathway implicated in SDF-1 activation. By inhibiting PDK1, GSK2334470 disrupts the downstream signaling events triggered by SDF-1, affecting cellular responses such as migration and activation mediated by the SDF-1/CXCR4 axis. | ||||||